Source comparison
BPC-157 Research Pregnancy Considerations: Comparison
Placental Transfer Data Confirmed in rodent models; crosses barrier within 90 minutes Assumed based on molecular weight (< 5 kDa); no direct pregnancy studies Minimal transfer; large molecule (5.8 kDa) with poor lipid solubility BPC-157 transfers more readily
This comparison does not assign a generated winner or score.
- Placental Transfer Data
- Confirmed in rodent models; crosses barrier within 90 minutes
- Assumed based on molecular weight (< 5 kDa); no direct pregnancy studies
- Minimal transfer; large molecule (5.8 kDa) with poor lipid solubility
- BPC-157 transfers more readily than larger biologics; mechanism similar to TB-500 but with more angiogenic activity
- Human Pregnancy Safety Data
- None. Zero clinical trials, zero observational cohorts
- None. Used off-label in sports medicine without pregnancy tracking
- Decades of use; extensive pregnancy category data; established dosing adjustments
- Complete absence of data means BPC-157 cannot be risk-stratified relative to known compounds
- Growth Factor Modulation
- Upregulates VEGF 2.5–4× baseline; affects FAK-paxillin pathway active in organogenesis
- Primarily actin regulation; less direct growth factor interaction
- Metabolic regulator; no direct developmental signaling pathway modulation
- BPC-157's angiogenic mechanism intersects directly with embryonic vascular development. Higher theoretical concern
- Recommended Washout Period
- 60–90 days before conception (extrapolated from tissue retention models)
- 30–60 days (based on serum half-life of 10–12 hours)
- Not discontinued during pregnancy when medically necessary; dose-adjusted
- Longer washout for BPC-157 reflects uncertainty, not confirmed risk. Conservative default in absence of data
- Regulatory Classification
- Research compound; not FDA-approved for any indication
- Research compound; no FDA approval
- FDA-approved therapeutic; pregnancy category B
- BPC-157 and TB-500 occupy identical regulatory space. Neither has undergone reproductive toxicity evaluation required for therapeutic approval